Obesity Paradox in Heart Failure with Mildly Reduced Ejection Fraction

References

• Savarese G, Becher PM, Lund LH, et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272–3287. doi:10.1093/cvr/cvac013
   PubMed Web of Science ®Google Scholar
• James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789–1858. doi:10.1016/S0140-6736(18)32279-7
   PubMed Web of Science ®Google Scholar
• Conrad N, Judge A, Tran J, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391(10120):572–580. doi:10.1016/S0140-6736(17)32520-5
   PubMed Web of Science ®Google Scholar
• Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017;70(20):2476–2486. doi:10.1016/j.jacc.2017.08.074
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975. doi:10.1002/ejhf.592
   PubMed Web of Science ®Google Scholar
• Carbone S, daSilva-deAbreu A, Lavie CJ. The sodium-glucose co-transporter 2 inhibitor dapagliflozin improves prognosis in systolic heart failure independent of the obesity paradox. Eur J Heart Fail. 2021;23(10):1673–1676. doi:10.1002/ejhf.2336
   PubMed Web of Science ®Google Scholar
• Thorvaldsen T, Ferrannini G, Mellbin L, et al. Eligibility for dapagliflozin and empagliflozin in a real-world heart failure population. J Card Fail. 2022;28(7):1050–1062. doi:10.1016/j.cardfail.2022.04.011
   PubMed Web of Science ®Google Scholar
• Solomon SD, Vaduganathan M, Claggett BL, et al. Baseline characteristics of patients with hf with mildly reduced and preserved ejection fraction: DELIVER trial. JACC Heart Fail. 2022;10(3):184–197. doi:10.1016/j.jchf.2021.11.006
   PubMed Web of Science ®Google Scholar
• Savarese G, Stolfo D, Sinagra G, et al. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19(2):100–116. doi:10.1038/s41569-021-00605-5
   PubMed Web of Science ®Google Scholar
• McDonagh TA, McDonagh TA, Metra M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24(1):4–131. doi:10.1002/ejhf.2333
   PubMed Web of Science ®Google Scholar
• Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. 2022;133:155217. doi:10.1016/j.metabol.2022.155217
   PubMedGoogle Scholar
• Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021;143(21):e984–e1010. doi:10.1161/CIR.0000000000000973
   PubMed Web of Science ®Google Scholar
• Liu Z, Peng Y, Zhao W, et al. Obesity increases cardiovascular mortality in patients with HFmrEF. Front Cardiovasc Med. 2022;9:967780. doi:10.3389/fcvm.2022.967780
   PubMedGoogle Scholar
• Benn M, Marott SCW, Tybjærg-Hansen A, et al. Obesity increases heart failure incidence and mortality: observational and Mendelian randomization studies totalling over 1 million individuals. Cardiovasc Res. 2023;118(18):3576–3585. doi:10.1093/cvr/cvab368
   PubMed Web of Science ®Google Scholar
• Simati S, Kokkinos A, Dalamaga M, et al. Obesity Paradox: fact or Fiction? Curr Obes Rep. 2023;12(2):75–85. doi:10.1007/s13679-023-00497-1
   PubMed Web of Science ®Google Scholar
• Tutor AW, Lavie CJ, Kachur S, Milani RV, Ventura HO. Updates on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis. 2022;78:2–10.
   PubMed Web of Science ®Google Scholar
• Zeng S, Cai X, Zheng Y, et al. Associations of body mass index with mortality in heart failure with preserved ejection fraction patients with ischemic versus non-ischemic etiology. Front Cardiovasc Med. 2022;9:966745. doi:10.3389/fcvm.2022.966745
   PubMedGoogle Scholar
• Kim SE, Lee CJ. The paradox in defining obesity in patients with heart failure. Int J Heart Fail. 2022;4(2):91–94. doi:10.36628/ijhf.2022.0010
   PubMedGoogle Scholar
• Giri Ravindran S, Saha D, Iqbal I, et al. The obesity paradox in chronic heart disease and chronic obstructive pulmonary disease. Cureus. 2022;14(6):e25674. doi:10.7759/cureus.25674
   PubMed Web of Science ®Google Scholar
• Li S, Zheng Y, Huang Y, et al. Association of body mass index and prognosis in patients with HFpEF: a dose-response meta-analysis. Int J Cardiol. 2022;361:40–46. doi:10.1016/j.ijcard.2022.05.018
   PubMed Web of Science ®Google Scholar
• Dong B, Yao Y, Xue R, et al. Distinct implications of body mass index in different subgroups of nonobese patients with heart failure with preserved ejection fraction: a latent class analysis of data from the TOPCAT trial. BMC Med. 2022;20(1):423. doi:10.1186/s12916-022-02626-4
   PubMed Web of Science ®Google Scholar
• Tadic M, Cuspidi C. Obesity and heart failure with preserved ejection fraction: a paradox or something else? Heart Fail Rev. 2019;24(3):379–385. doi:10.1007/s10741-018-09766-x
   PubMed Web of Science ®Google Scholar
• Alrob OA, Sankaralingam S, Alazzam S, et al. Obesity paradox among heart failure with reduced ejection fraction patients: a retrospective cohort study. Medicina. 2022;59(1):60. doi:10.3390/medicina59010060
   PubMedGoogle Scholar
• Wenzel JP, Nikorowitsch J, Bei der Kellen R, et al. Heart failure in the general population and impact of the 2021 European Society of Cardiology Heart Failure Guidelines. ESC Heart Fail. 2022;9(4):2157–2169. doi:10.1002/ehf2.13948
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• Popescu BA, Andrade MJ, Badano LP, et al. European Association of Echocardiography recommendations for training, competence, and quality improvement in echocardiography. Eur J Echocardiograp. 2009;10(8):893–905. doi:10.1093/ejechocard/jep151
   PubMed Web of Science ®Google Scholar
• Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2013;14(7):611–644. doi:10.1093/ehjci/jet105
   PubMed Web of Science ®Google Scholar
• Badimon L, Bugiardini R, Cenko E, et al. Position paper of the European Society of Cardiology-working group of coronary pathophysiology and microcirculation: obesity and heart disease. Eur Heart J. 2017;38(25):1951–1958. doi:10.1093/eurheartj/ehx181
   PubMed Web of Science ®Google Scholar
• Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53(21):1925–1932. doi:10.1016/j.jacc.2008.12.068
   PubMed Web of Science ®Google Scholar
• Horwich TB, Fonarow GC, Clark AL. Obesity and the Obesity Paradox in Heart Failure. Prog Cardiovasc Dis. 2018;61(2):151–156. doi:10.1016/j.pcad.2018.05.005
   PubMed Web of Science ®Google Scholar
• Kenchaiah S, Pocock SJ, Wang D, et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007;116(6):627–636. doi:10.1161/CIRCULATIONAHA.106.679779
   PubMed Web of Science ®Google Scholar
• Oreopoulos A, Padwal R, Kalantar-Zadeh K, et al. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008;156(1):13–22. doi:10.1016/j.ahj.2008.02.014
   PubMed Web of Science ®Google Scholar
• Madamanchi C, Alhosaini H, Sumida A, et al. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014;176(3):611–617. doi:10.1016/j.ijcard.2014.08.007
   PubMed Web of Science ®Google Scholar
• Padwal R, McAlister FA, McMurray JJV, et al. The obesity paradox in heart failure patients with preserved versus reduced ejection fraction: a meta-analysis of individual patient data. Int J Obes. 2014;38(8):1110–1114. doi:10.1038/ijo.2013.203
   PubMed Web of Science ®Google Scholar
• Zhang J, Begley A, Jackson R, et al. Body mass index and all-cause mortality in heart failure patients with normal and reduced ventricular ejection fraction: a dose-response meta-analysis. Clin Res Cardiol. 2019;108(2):119–132. doi:10.1007/s00392-018-1302-7
   PubMed Web of Science ®Google Scholar
• Milajerdi A, Djafarian K, Shab‐Bidar S, et al. Pre- and post-diagnosis body mass index and heart failure mortality: a dose-response meta-analysis of observational studies reveals greater risk of being underweight than being overweight. Obes Rev. 2018;20(2):252–261. doi:10.1111/obr.12777
   PubMed Web of Science ®Google Scholar
• Adamson C, Kondo T, Jhund PS, et al. Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J. 2022;43(41):4406–4417. doi:10.1093/eurheartj/ehac481
   PubMed Web of Science ®Google Scholar
• Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–1392. doi:10.1056/NEJMoa1313731
   PubMed Web of Science ®Google Scholar